ArticleJournal for immunotherapy of cancer2025
Phase 1 study evaluating the safety, preliminary efficacy, and pharmacodynamics of recombinant interleukin-15 in combination with nivolumab and ipilimumab in patients with refractory cancers.
Jibran Ahmed et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.